From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
TPO agonist 1 is a thrombopoietin (TPO) agonist extracted from patent WO2008134338A1, compound TPO mimetic. It would be useful as promoters of thrombopoiesis and megakaryocytopoiesis to treat thrombocytopenia .
Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .
Avatrombopag (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .
TPO Human Pre-designed siRNA Set A contains three designed siRNAs for TPO gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Avatrombopag maleate (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag maleate mimics the biological activities of TPO. Avatrombopag maleate increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag maleate is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .
MPO-IN-1 is a potent, orally active, and irreversible indole-containing inhibitor of myeloperoxidase (MPO). MPO-IN-1 has IC50s of 2.6 μM and 5.3 μM for MPO and thyroid peroxidase (TPO), respectively. MPO-IN-1 inhibits MPO activity in an acute mouse model of inflammation .
Lusutrombopag-d13 is deuterium labeled Lusutrombopag. Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease.
Eltrombopag methyl ester is a derivative of Eltrombopag, which is a thrombopoietin (Tpo) receptor agonist, which can promote platelet production and is used in research related to specific types of thrombocytopenia .
Avatrombopag-d8 (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A[1][2][3].
Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of human platelets in mouse xenotransplantation assay .
TA-3166 (Megakaryocytes/platelets inducing agent) is a novel chemically synthesized c-MPL agonist (CMA) and thrombopoietin (TPO) receptor agonist. TA-316 enhances ex vivo platelet generation from human-induced pluripotent stem (iPS) cells .
Eltrombopag- 13C4 (SB-497115- 13C4) is 13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells .
MPO-IN-5 (compound 1) is a potent, irreversible MPO (myeloperoxidase) inhibitor. MPO-IN-5 inhibits MPO peroxidation and hERG binding, with IC50 values of 0.22 and 2.8 μM, respectively. MPO-IN-5 shows rapid kinetics of inhibition, with enzyme inactivation rate (kinact/Ki) of 23000 M −1s −1 .
TPO/Thrombopoietin Protein, Human (CHO)，also called megakaryocyte growth and development factor, is a cytokine that regulates megakaryocyte and platelet production.
TPO/Thrombopoietin Protein, a lineage-specific cytokine, crucially regulates megakaryocyte proliferation and maturation, acting in the late stages of development from committed progenitor cells. Recognized as a major physiological regulator, TPO significantly influences circulating platelets, emphasizing its importance in the intricate process of platelet formation. TPO/Thrombopoietin Protein, Mouse (HEK293) is the recombinant mouse-derived TPO/Thrombopoietin protein, expressed by HEK293 , with tag free. The total length of TPO/Thrombopoietin Protein, Mouse (HEK293) is 335 a.a., with molecular weight (glycosylation form) of ~28-40 kDa.
Thyroid peroxidase (TPO) plays a pivotal role in iodination and coupling of tyrosines in thyroglobulin, crucial for synthesizing essential thyroid hormones T(3) and T(4). TPO/Thyroid peroxidase Protein, Human (A257S, T725P, sf9, His) is the recombinant human-derived TPO/Thyroid peroxidase protein, expressed by Sf9 insect cells , with C-10*His labeled tag. The total length of TPO/Thyroid peroxidase Protein, Human (A257S, T725P, sf9, His) is 832 a.a., with molecular weight of 90-100 kDa.
Thyroid Peroxidase (TPO) orchestrates iodination and coupling within thyroglobulin, leading to the synthesis of thyroid hormones T(3) and T(4). TPO/Thyroid Peroxidase Protein, Mouse (HEK293, His) is the recombinant mouse-derived TPO/Thyroid Peroxidase protein, expressed by HEK293 , with C-His labeled tag. The total length of TPO/Thyroid Peroxidase Protein, Mouse (HEK293, His) is 803 a.a., with molecular weight of 100-115 kDa.
The C-MPL Protein, a receptor for thrombopoietin, is a protein encoded in humans by the oncogene of myeloproliferative leukemia virus. The C-MPL Protein is involved in the activation of the JAK/STAT/MAPK signaling pathway. C-MPL Protein is a biomarker for thrombocytopenia. C-MPL Protein, Rat (sf9, His) is the recombinant rat-derived C-MPL protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of C-MPL Protein, Rat (sf9, His) is 500 a.a., with molecular weight of ~55 kDa.
The C-MPL Protein, a receptor for thrombopoietin, is a protein encoded in humans by the oncogene of myeloproliferative leukemia virus. The C-MPL Protein is involved in the activation of the JAK/STAT/MAPK signaling pathway. C-MPL Protein is a biomarker for thrombocytopenia. C-MPL Protein, Rat (HEK293, Fc) is the recombinant rat-derived C-MPL protein, expressed by HEK293 , with C-hFc labeled tag. The total length of C-MPL Protein, Rat (HEK293, Fc) is 479 a.a., with molecular weight of ~80.7 kDa.
C-MPL Protein, the thrombopoietin receptor, is a pivotal regulator of megakaryopoiesis and platelet production, suggesting a specific role in TPO-R-dependent immune responses. Forming homodimers and interacting with ATXN2L, it contributes to its multifaceted role in hematopoiesis and immune modulation. C-MPL Protein, Human (HEK293, His) is the recombinant human-derived C-MPL protein, expressed by HEK293 , with C-His labeled tag. The total length of C-MPL Protein, Human (HEK293, His) is 466 a.a., with molecular weight of 68-70 kDa.
C-MPL Protein, the receptor for thrombopoietin (TPO), is a key regulator of megakaryopoiesis and platelet production. It plays a crucial role in TPO-R-dependent immune responses and inhibits thrombopoietin signaling by facilitating the down-regulation of the full-length isoform Mpl-fl. C-MPL Protein, Mouse (HEK293, His) is the recombinant mouse-derived C-MPL protein, expressed by HEK293 , with C-His labeled tag. The total length of C-MPL Protein, Mouse (HEK293, His) is 457 a.a., with molecular weight of 65-70 kDa.
C-MPL protein is a key member of the type I cytokine receptor family and is essential for mediating cellular responses to various cytokines. Its research enhances our understanding of cell signaling, providing potential applications for therapeutic intervention in hematopoietic disorders and immune disorders. C-MPL Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived C-MPL protein, expressed by HEK293 , with C-His labeled tag. The total length of C-MPL Protein, Cynomolgus (HEK293, His) is 468 a.a., with molecular weight of 60-70 kDa.
TPO/Thrombopoietin Protein, Human (HEK 293, His) is a recombinant protein produced in HEK293 cells with a His tag. TPO is a growth factor for the megakaryocytic/platelet lineage.
TPO/Thrombopoietin Protein, Human (HEK 293, His) is a recombinant protein produced in HEK293 cells with a His tag. TPO is a growth factor for the megakaryocytic/platelet lineage.
TPO/Thrombopoietin Protein, a lineage-specific cytokine, crucially regulates megakaryocyte proliferation and maturation, acting in the late stages of development from committed progenitor cells. Recognized as a major physiological regulator, TPO significantly influences circulating platelets, emphasizing its importance in the intricate process of platelet formation. TPO/Thrombopoietin Protein, Mouse (335a.a, HEK293, His) is the recombinant mouse-derived TPO/Thrombopoietin protein, expressed by HEK293 , with N-6*His labeled tag. The total length of TPO/Thrombopoietin Protein, Mouse (335a.a, HEK293, His) is 335 a.a., with molecular weight of 80-110 kDa.
TPO/Thrombopoietin Protein, a lineage-specific cytokine, crucially regulates megakaryocyte proliferation and maturation, acting in the late stages of development from committed progenitor cells. Recognized as a major physiological regulator, TPO significantly influences circulating platelets, emphasizing its importance in the intricate process of platelet formation. TPO/Thrombopoietin Protein, Mouse (335a.a, HEK293, C-His) is the recombinant mouse-derived TPO/Thrombopoietin protein, expressed by HEK293 , with C-6*His labeled tag. The total length of TPO/Thrombopoietin Protein, Mouse (335a.a, HEK293, C-His) is 335 a.a., with molecular weight of approximately 75 kDa.
TPO/Thrombopoietin Protein, a lineage-specific cytokine, significantly influences megakaryocyte proliferation and maturation, particularly in late developmental stages from committed progenitor cells. It emerges as a potential major physiological regulator, underscoring its crucial role in the intricate orchestration of circulating platelets and emphasizing its importance in megakaryocyte biology and platelet formation. GMP TPO/Thrombopoietin Protein, Human (HEK293, His) is the recombinant human-derived TPO/Thrombopoietin protein, expressed by HEK293 , with C-6*His labeled tag. The total length of GMP TPO/Thrombopoietin Protein, Human (HEK293, His) is 332 a.a., with molecular weight of 70-90 kDa.
TPO/Thrombopoietin Protein, a lineage-specific cytokine, significantly influences megakaryocyte proliferation and maturation, particularly in late developmental stages from committed progenitor cells. It emerges as a potential major physiological regulator, underscoring its crucial role in the intricate orchestration of circulating platelets and emphasizing its importance in megakaryocyte biology and platelet formation. Animal-Free TPO/Thrombopoietin Protein, Human (His) is the recombinant human-derived animal-FreeTPO/Thrombopoietin protein, expressed by E. coli , with N-His labeled tag. The total length of Animal-Free TPO/Thrombopoietin Protein, Human (His) is 174 a.a., with molecular weight of ~19.6 kDa.
Eltrombopag- 13C4 (SB-497115- 13C4) is 13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells .
Lusutrombopag-d13 is deuterium labeled Lusutrombopag. Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease.
Avatrombopag-d8 (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A[1][2][3].
